US2019153384A1PendingUtilityA1

Human lambda light chain mice

Assignee: REGENERON PHARMAPriority: Jun 22, 2010Filed: Feb 6, 2019Published: May 23, 2019
Est. expiryJun 22, 2030(~3.9 yrs left)· nominal 20-yr term from priority
A01K 67/0275C12N 2015/8518C07K 16/18A01K 2267/01A01K 2227/105A01K 2217/07C07K 2317/24C07K 16/461C07K 16/462C07K 2317/64A01K 2267/0381C12N 15/10C12N 5/0606A01K 2217/15C07K 2317/14A01K 2207/15C07K 2317/50C07K 2317/515C07K 16/00C07K 2317/56A01K 2217/052C07K 2317/21C12N 15/8509A01K 2217/072A01K 67/0278A01K 2217/05C07K 2317/10A01K 2267/02C12N 2800/30A01K 67/027C07K 16/46
75
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Genetically modified mice are provided that express human λ variable (hVλ) sequences, including mice that express hVλ sequences from an endogenous mouse λ light chain locus, mice that express hVλ sequences from an endogenous mouse κ light chain locus, and mice that express hVλ, sequences from a transgene or an episome wherein the hVλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human λ variable sequences, including human antibodies, are provided.

Claims

exact text as granted — not AI-modified
1 - 20 . (canceled) 
     
     
         21 . A genetically modified mouse, whose genome comprises:
 (a) one or more unrearranged human Vλ gene segments,   (b) one or more unrearranged human Jλ gene segments, and   (c) one or more human Cλ gene segments,   wherein the one or more unrearranged human Vλ gene segments of (a) and the one or more unrearranged human Jλ gene segments of (b) are at an endogenous mouse λ light chain locus.   
     
     
         22 . The genetically modified mouse of  claim 21 , wherein the endogenous mouse λ light chain locus comprises one or more mouse Cλ gene segments. 
     
     
         23 . The genetically modified mouse of  claim 22 , wherein the one or more mouse Cλ gene segments is one mouse Cλ gene segment. 
     
     
         24 . (canceled) 
     
     
         25 . The genetically modified mouse of  claim 22 ,
 wherein the one or more unrearranged human Vλ gene segments of (a) and the one or more unrearranged human Jλ gene segments of (b) are operably linked to the one or more human Cλ gene segments of (c), and   wherein the one or more unrearranged human Vλ gene segments of (a) and the one or more unrearranged human Jλ gene segments of (b) are operably linked to the one or more mouse Cλ gene segments.   
     
     
         26 . The genetically modified mouse of  claim 21 , wherein the one or more human Cλ gene segments comprise at least four human Cλ gene segments. 
     
     
         27 . The genetically modified mouse of  claim 21 , wherein the one or more human Cλ gene segments comprise five human Cλ gene segments. 
     
     
         28 . The genetically modified mouse of  claim 21 , wherein the one or more unrearranged human Jλ gene segments comprise a human Jλ1 gene segment. 
     
     
         29 . The genetically modified mouse of  claim 21 , wherein the one or more unrearranged human Jλ gene segments comprise at least four human Jλ gene segments. 
     
     
         30 . The genetically modified mouse of  claim 21 , wherein the one or more unrearranged human Jλ gene segments comprise at least five human Jλ gene segments. 
     
     
         31 . The genetically modified mouse of  claim 29 , wherein the at least four human Jλ gene segments are Jλ1, Jλ2, Jλ3 and Jλ7. 
     
     
         32 . The genetically modified mouse of  claim 21 , wherein the one or more unrearranged human Vλ gene segments comprise at least 12 human Vλ gene segments. 
     
     
         33 . (canceled) 
     
     
         34 . The genetically modified mouse of  claim 21 , wherein the one or more unrearranged human Vλ gene segments comprise at least 28 human Vλ gene segments. 
     
     
         35 - 36 . (canceled) 
     
     
         37 . The genetically modified mouse of  claim 21 , wherein one or more mouse enhancers are maintained at the endogenous mouse λ light chain locus. 
     
     
         38 . The genetically modified mouse of  claim 21 , wherein the endogenous mouse λ light chain locus further comprises one or more human enhancers. 
     
     
         39 . The genetically modified mouse of  claim 38 , wherein the one or more human enhancers are λ light chain enhancers. 
     
     
         40 . The genetically modified mouse of  claim 21 , wherein the one or more unrearranged human Jλ gene segments of (b) and the one or more human Cλ gene segments of (c) are present as J-C clusters. 
     
     
         41 . The genetically modified mouse of  claim 21 , wherein the mouse produces antibodies comprising human lambda variable domains. 
     
     
         42 . The genetically modified mouse of  claim 21 , wherein the one or more unrearranged human Vλ gene segments comprise Vλ3-1, Vλ4-3, Vλ2-8, Vλ3-9, Vλ3-10, Vλ2-11, Vλ3-12 or a combination thereof. 
     
     
         43 . The genetically modified mouse of  claim 21 , wherein the one or more unrearranged human Vλ gene segments comprise human Vλ2-14, Vλ3-16, Vλ2-18, Vλ3-19, Vλ3-21, Vλ3-22, Vλ2-23, Vλ3-25, Vλ3-27 or a combination thereof. 
     
     
         44 . The genetically modified mouse of  claim 21 , wherein the one or more unrearranged human Vλ gene segments comprise human Vλ1-40, Vλ7-43, Vλ1-44, Vλ5-45, Vλ7-46, Vλ1-47, Vλ9-49, Vλ1-51, Vλ5-52 or a combination thereof. 
     
     
         45 . The genetically modified mouse of  claim 21 , wherein the genetically modified mouse expresses an antibody comprising a human light chain variable domain expressed from a rearranged human lambda light chain variable region derived from a human Vλ gene segment of the one or more unrearranged human Vλ gene segments of (a) and a human Jλ gene segment of the one or more unrearranged human Jλ gene segments of (b). 
     
     
         46 . The genetically modified mouse of  claim 45 , wherein the human Vλ gene segment from which the rearranged human lambda light chain variable region is derived is a human Vλ3-1, Vλ4-3, Vλ2-8, Vλ3-9, Vλ3-10, Vλ2-14, Vλ3-19, Vλ2-23, Vλ3-25, Vλ1-40, Vλ7-43, Vλ1-44, Vλ5-45, Vλ7-46, Vλ9-49, Vλ1-51, Vλ1-47, or Vλ7-46. 
     
     
         47 . The genetically modified mouse of  claim 42 , wherein the one or more human Vλ gene segments from which the rearranged human lambda light chain variable region is derived is a human Vλ3-1, Vλ4-3, Vλ2-8, Vλ3-9, or Vλ3-10. 
     
     
         48 . The genetically modified mouse of  claim 43 , wherein the one or more human Vλ gene segments from which the rearranged human lambda light chain variable region is derived is a human Vλ2-14, Vλ3-16, Vλ2-18, Vλ3-19, Vλ3-21, Vλ3-22, Vλ2-23, Vλ3-25, or Vλ3-27. 
     
     
         49 . The genetically modified mouse of  claim 21 , wherein the human Jλ gene segment from which the rearranged human lambda light chain variable region is derived is a human Jλ1, Jλ2, Jλ3, or Jλ7. 
     
     
         50 . The genetically modified mouse of  claim 21 , wherein the genome of the genetically modified mouse includes an endogenous lambda light chain variable region sequence. 
     
     
         51 . The genetically modified mouse of  claim 21 , comprising:
 at least two λ light chain enhancers downstream of both the one or more unrearranged human Vλ gene segments and the one or more unrearranged human Jλ gene segments.   
     
     
         52 . The genetically modified mouse of  claim 21 , wherein the one or more unrearranged human Vλ gene segments of (a) and the one or more unrearranged human Jλ gene segments of (b) are operably linked to the one or more human Cλ gene segments of (c). 
     
     
         53 . The genetically modified mouse of  claim 21 , wherein the one or more unrearranged human Jλ gene segments comprise at least two human Jλ gene segments. 
     
     
         54 . The genetically modified mouse of  claim 21 , wherein the one or more unrearranged human Jλ gene segments comprise at least three human Jλ gene segments.

Join the waitlist — get patent alerts

Track US2019153384A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.